Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement
Source : https://pubmed.ncbi.nlm.nih.gov/38576288/
Papillary thyroid carcinoma, Hashimoto's thyroiditis, BRAF V600E protein, RET gene rearrangement.
There is a lower rate of BRAF V600E protein positivity in papillary thyroid carcinoma with comorbid Hashimoto thyroiditis, as well as a higher rate of RET rearrangements positive in papillary thyroid carcinoma with comorbid Hashimoto thyroiditis.
Targeted Therapeutic Options in Early and Metastatic NSCLC-Overview
Source : https://www.por-journal.com/articles/10.3389/pore.2024.1611715/full
The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well...
Incorporating reflex testing with next-generation sequencing expands personalized therapies by identifying guideline-recommended molecular alterations.
RET Splice Site Variants in Medullary Thyroid Carcinoma
Source : https://pubmed.ncbi.nlm.nih.gov/38566816/
Introduction: Medullary thyroid carcinoma (MTC) is an aggressive cancer that is often caused by driver mutations in RET . Splice site variants (SSV) reflect changes in mRNA processing, which may...
All 25 medullary thyroid carcinoma specimens analyzed had at least one of the 2 most common RET slice site variants, including 4 with no identified mutational driver.
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors
Source : https://pubmed.ncbi.nlm.nih.gov/38523069/
Activation of RET tyrosine kinase plays a critical role in the pathogenesis of various cancers, including non-small cell lung cancer, papillary thyroid cancers, multiple endocrine neoplasia type 2A and 2B...
Extensive small molecule libraries were screened using developed ligand-based models and potent compounds which are capable of inhibiting RET activation were proposed.
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors
Source : https://pubmed.ncbi.nlm.nih.gov/38523069/
Activation of RET tyrosine kinase plays a critical role in the pathogenesis of various cancers, including non-small cell lung cancer, papillary thyroid cancers, multiple endocrine neoplasia type 2A and 2B...
Extensive small molecule libraries were screened using developed ligand-based models and potent compounds which are capable of inhibiting RET activation were proposed.